Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy
-
Published:2020-09-08
Issue:1
Volume:4
Page:
-
ISSN:2397-768X
-
Container-title:npj Precision Oncology
-
language:en
-
Short-container-title:npj Precis. Onc.
Author:
Recondo GonzaloORCID, Mahjoubi Linda, Maillard Aline, Loriot Yohann, Bigot Ludovic, Facchinetti Francesco, Bahleda Rastislav, Gazzah Anas, Hollebecque Antoine, Mezquita Laura, Planchard David, Naltet Charles, Lavaud Pernelle, Lacroix Ludovic, Richon Catherine, Lovergne Aurelie Abou, De Baere Thierry, Tselikas Lambros, Deas Olivier, Nicotra Claudio, Ngo-Camus Maud, Frias Rosa L., Solary Eric, Angevin Eric, Eggermont Alexander, Olaussen Ken A., Vassal Gilles, Michiels StefanORCID, Andre FabriceORCID, Scoazec Jean-Yves, Massard Christophe, Soria Jean-Charles, Besse Benjamin, Friboulet LucORCID
Abstract
AbstractUnravelling the biological processes driving tumour resistance is necessary to support the development of innovative treatment strategies. We report the design and feasibility of the MATCH-R prospective trial led by Gustave Roussy with the primary objective of characterizing the molecular mechanisms of resistance to cancer treatments. The primary clinical endpoints consist of analyzing the type and frequency of molecular alterations in resistant tumours and compare these to samples prior to treatment. Patients experiencing disease progression after an initial partial response or stable disease for at least 24 weeks underwent a tumour biopsy guided by CT or ultrasound. Molecular profiling of tumours was performed using whole exome sequencing, RNA sequencing and panel sequencing. At data cut-off for feasibility analysis, out of 333 inclusions, tumour biopsies were obtained in 303 cases (91%). From these biopsies, 278 (83%) had sufficient quality for analysis by high-throughput next generation sequencing (NGS). All 278 samples underwent targeted NGS, 215 (70.9%) RNA sequencing and 222 (73.2%) whole exome sequencing. In total, 163 tumours were implanted in NOD scid gamma (NSG) or nude mice and 54 patient-derived xenograft (PDX) models were established, with a success rate of 33%. Adverse events secondary to invasive tumour sampling occurred in 24 patients (7.6%). Study recruitment is still ongoing. Systematic molecular profiling of tumours and the development of patient-derived models of acquired resistance to targeted agents and immunotherapy is feasible and can drive the selection of the next therapeutic strategy.
Publisher
Springer Science and Business Media LLC
Subject
Computer Science Applications,History,Education
Reference35 articles.
1. DeVita, V. T. J., Eggermont, A. M. M., Hellman, S. & Kerr, D. J. Clinical cancer research: the past, present and the future. Nat. Rev. Clin. Oncol. 11, 663–669 (2014). 2. Koboldt, D. C., Steinberg, K. M., Larson, D. E., Wilson, R. K. & Mardis, E. R. The next-generation sequencing revolution and its impact on genomics. Cell 155, 27–38 (2013). 3. Crystal, A. S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science https://doi.org/10.1126/science.1254721 (2014). 4. Ferguson, F. M. & Gray, N. S. Kinase inhibitors: the road ahead. Nat. Rev. Drug Discov. 17, 353–376 (2018). 5. Tang, J., Pearce, L., O’Donnell-Tormey, J. & Hubbard-Lucey, V. M. Trends in the global immuno-oncology landscape. Nat. Rev. Drug Discov. 17, 783–784 (2018).
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|